Clement C Zai

Associate Professor

University of Toronto
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Year:

2026

Pharmacogenomics enables the personalization of drug therapy by linking genetic variations to differences in drug metabolism, efficacy, and risk of adverse reactions. Genetic polymorphisms within cytochrome P450 (CYP) genes significantly affect enzyme activity, influencing drug plasma levels, responses, and safety. Central to this process is accurate genotype‐to‐phenotype translation, especially for the CYP enzyme family, which metabolizes 70–80% of clinically used drugs. To address this, we have developed GenoStaR, an R package that converts genotypes into star alleles and predicts the associated metabolizer status for major cytochrome P450 genes— CYP1A2 , CYP2B6 , CYP2C9 , CYP2C19 , CYP2D6 , CYP3A4 , and CYP3A5 . GenoStaR assigns star alleles using single‐nucleotide polymorphisms, insertion–deletion variants, and structural variants. Given genotype data, GenoStaR uses comprehensive allele definition tables to determine diplotypes, activity scores, and predicted metabolizer status. The tool accounts for complex scenarios, including CYP2D6 copy number variations, using a tiered matching strategy and structural variant detection. We evaluated GenoStaR using two datasets. The first from the Centre for Addiction and Mental Health Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment (IMPACT) study ( n = 8,287), which included genotyping data, along with star allele information from a commercial pharmacogenetic test. The second, the Toronto Schizophrenia sample ( n = 188), with in‐house genotype data and manually validated star alleles. GenoStaR achieved 100% concordance in diplotype calls across both datasets. GenoStaR offers a reliable, efficient, and accurate solution for converting genotypes into star alleles and predicting CYP‐related metabolizer status. Its performance on a large validation dataset highlights its potential to enhance pharmacogenomic testing in clinical settings.

Year:

2026

Mitochondrial dysfunction is implicated in the neuropathology of bipolar disorder (BD). Mitochondrial DNA (mtDNA) variants are associated with anomalous cerebral energy metabolism and with increased risk for BD. Little is known about the relevance of mtDNA to cerebral blood flow (CBF) in BD. Participants included 101 youth (BD, n = 56; Control group, n = 45; ages 13–20). The Miseq platform was used to sequence saliva mtDNA. The mtDNA-Server pipeline was used for variant calling and annotation. mtDNA common variants (i.e. minor allele frequency larger than 5%) were included in the analyses due to sample size. We generated an mtDNA variant functional impact (FI) score by performing functional analysis using Mutserve and summing across the MutPred, Selection Score, and MitoTool algorithms. CBF was measured using pseudo-continuous arterial spin labeling magnetic resonance imaging. Region of interest (ROI) analyses examined FI scores in relation to CBF in the anterior cingulate cortex (ACC) and global gray matter, controlling for age and sex. Voxel-based analyses were also conducted. In ROI analyses, higher mtDNA FI score was associated with higher ACC CBF in the overall sample (β = 0.20, p = 0.045). In voxel-based analyses, higher mtDNA FI score was associated with higher CBF in regions within the basal ganglia, frontal and parietal lobe, and cingulate within the overall sample and within the BD group. This study found that higher mtDNA FI score, putatively reflecting mtDNA pathogenicity, was associated with higher regional CBF among youth. Present findings add to the evidence that elevated CBF may be a compensatory mechanism in youth with BD.

Year:

2025

Obsessive-compulsive disorder (OCD) is a severe neuropsychiatric disorder with clear evidence of genetic vulnerability, although specific risk factors are not fully understood. Mitochondrial dysfunction has been implicated in other severe neuropsychiatric disorders, particularly through its role in oxidative stress, and thus merits exploration in OCD. Here we first examined the association of a set of 59 mitochondrial single nucleotide polymorphisms (SNPs) with OCD symptom severity. These SNPs are located inside 28 nuclear-encoded mitochondrial genes involved in oxidative phosphorylation, oxidative stress, mitochondrial biogenesis, inflammation, and apoptosis. We used linear regression to test for the association of this SNP set with symptom severity using the Yale-Brown Obsessive Compulsive Scale (YBOCS). We found a nominally significant association for rs3820189 in the 5’ of the MFN2 gene with YBOCS total score (N = 346; P uncorrected = 0.002). We also conducted gene-based and gene-set (pathway) analyses on nuclear-encoded mitochondrial genes and pathways with OCD risk using MAGMA. We found the gene ADCK1 to be associated with OCD (p = 0.00005, q = 0.05). No mitochondrial pathways were associated with OCD risk. To further examine mitochondrial genetic variation in OCD risk, we then examined mitochondrial (mt) DNA (mtDNA), the circular genome located inside each mitochondrion. We utilized the Toronto OCD sample (N = 215) and the 1000 Genome Project (N = 485) as healthy controls for discovery. For replication, we compared individual-level data from the Psychiatric Genomics Consortium (PGC) OCD Working Group release 2017 (N = 1691) with the Wellcome Trust sample (N = 2616) as controls. After data cleaning, 58 common mtDNA SNPs (minor allele frequency greater than 1%) were available for analysis. Meta-analysis across the significant mtDNA variants shared between both samples revealed five SNPs significantly associated with OCD risk which survived Nyholt correction: NC_012920.1:m.1719G > A (P = 1.489E-05), NC_012920.1:m.3010G > A (P = 2.423E-05), NC_012920.1:m.10398A > G (P = 3.172E-04), NC_012920.1:m.11914G > A (P = 6.085E-04) and NC_012920.1:m.6260G > A (P = 7.792E-04). To the best of our knowledge, this is the largest study to report the involvement of mitochondrial variants in OCD risk. Further investigations and validation of our findings are warranted.

Year:

2025

Excessive and persistent aggressiveness is the most common behavioral problem that leads to psychiatric referrals among children. While half of the variance in childhood aggression is attributed to genetic factors, the biological mechanism and the interplay between genes and environment that results in aggression remains elusive. The purpose of this systematic review is to provide an overview of studies examining the genetics of childhood aggression irrespective of psychiatric diagnosis. PubMed, PsycINFO, and MEDLINE databases were searched using predefined search terms for aggression, genes and the specific age group. From the 652 initially yielded studies, eighty-seven studies were systematically extracted for full-text review and for further quality assessment analyses. Findings show that (i) investigation of candidate genes, especially of MAOA (17 studies), DRD4 (13 studies), and COMT (12 studies) continue to dominate the field, although studies using other research designs and methods including genome-wide association and epigenetic studies are increasing, (ii) the published articles tend to be moderate in sizes, with variable methods of assessing aggressive behavior and inconsistent categorizations of tandem repeat variants, resulting in inconclusive findings of genetic main effects, gene-gene, and gene-environment interactions, (iii) the majority of studies are conducted on European, male-only or male-female mixed, participants. To our knowledge, this is the first study to systematically review the effects of genes on youth aggression. To understand the genetic underpinnings of childhood aggression, more research is required with larger, more diverse sample sets, consistent and reliable assessments and standardized definition of the aggression phenotypes. The search for the biological mechanisms underlying child aggression will also benefit from more varied research methods, including epigenetic studies, transcriptomic studies, gene system and genome-wide studies, longitudinal studies that track changes in risk/ameliorating factors and aggression-related outcomes, and studies examining causal mechanisms.

Year:

2024

Schizophrenia (SCZ) and schizoaffective disorder (SAD) are severe and complex psychiatric disorders whose liability threshold is modulated by the interplay of biological, mainly genetic, and environmental factors. Consistent evidence has pointed to the role of serum brain‐derived neurotrophic factor (BDNF) as a plausible illness biomarker in SCZ spectrum disorders. There is no consensus, however, on the temporal trajectory of this decline. Here, we present a secondary analysis of the Longitudinal Assessment of BDNF in Sardinian Psychotic patients (LABSP) study, focusing on the impact of antipsychotic therapy, particularly long‐acting injectable (LAI), on the longitudinal trajectory of serum BDNF levels and analyzing the effect of BDNF genetic variants. LABSP patients were assessed every 6 months for a series of measures, including the assessment of BDNF serum levels over 24 months. Blood samples for each patient were taken at the same time of the day (between 8:00 and 10:00 a.m.). BDNF serum levels were determined using the BDNF ELISA Kit. Four tag single nucleotide polymorphisms (SNPs) within the BDNF gene (rs1519480, rs11030104, rs6265 [Val66Met], and rs7934165) were selected using standard parameters and analyzed with polymerase chain reaction (PCR). Mixed‐effects linear regression models (MLRMs) were used to analyze longitudinal data. Twenty‐four patients out of 105 LABSP (22.9%) patients received therapy with LAI. Analysis with MLRM showed a significant effect of LAI treatment associated with increasing serum BDNF levels ( Z = 2.2, p = 0.02). However, oral antipsychotics did not significantly impact the longitudinal trajectory of serum BDNF levels ( Z = 0.15, p = 0.9). There was no moderating effect of variants within the BDNF gene on the identified association. We identified a significant longitudinal increase in serum BDNF in SCZ and SAD patients treated with LAI antipsychotic therapy. The significant impact of this preparation of antipsychotic treatment on serum BDNF, despite the limited sample size, points to a moderate to large magnitude of effect that should be investigated in future prospective studies.

Year:

2024

Year:

2024

Year:

2024

Objectives The pathology of Tardive Dyskinesia (TD) has yet to be fully understood, but there have been proposed hypotheses for the cause of this condition. Our team previously reported a possible association of TD with the Complement Component C4 gene in the HLA region. In this study, we explored the HLA region further by examining two previously identified schizophrenia‐associated HLA‐region single‐nucleotide polymorphisms (SNPs), namely rs13194504 and rs210133. Methods The SNPs rs13194504 and rs210133 were tested for association with the occurrence and severity of TD in a sample of 172 schizophrenia patients who were recruited for four studies from three different clinical sites in Canada and USA. Results The rs13194504 AA genotype was associated with decreased severity for TD as measured by Abnormal Involuntary Movement Scale (AIMS) scores ( p = 0.047) but not for TD occurrence. SNP rs210133 was not significantly associated with either TD occurrence or AIMS scores. Conclusion Our findings suggest that the rs13194504 AA genotype may play a role in TD severity, while SNP rs210133 may not have a major role in the risk or severity of TD.

Year:

2024

In recent years, significant efforts have been made to improve methods for genomic studies of admixed populations using Local Ancestry Inference (LAI). Accurate LAI is crucial to ensure downstream analyses reflect the genetic ancestry of research participants accurately. Here, we test analytic strategies for LAI to provide guidelines for optimal accuracy, focusing on admixed populations reflective of Latin America’s primary continental ancestries – African (AFR), Amerindigenous (AMR), and European (EUR). Simulating LD-informed admixed haplotypes under a variety of 2 and 3-way admixture models, we implemented a standard LAI pipeline, testing three reference panel compositions to quantify their overall and ancestry-specific accuracy. We examined LAI miscall frequencies and true positive rates (TPR) across simulation models and continental ancestries. AMR tracts have notably reduced LAI accuracy as compared to EUR and AFR tracts in all comparisons, with TPR means for AMR ranging from 88-94%, EUR from 96-99% and AFR 98-99%. When LAI miscalls occurred, they most frequently erroneously called European ancestry in true Amerindigenous sites. Using a reference panel well-matched to the target population, even with a lower sample size, LAI produced true-positive estimates that were not statistically different from a high sample size but mismatched reference, while being more computationally efficient. While directly responsive to admixed Latin American cohort compositions, these trends are broadly useful for informing best practices for LAI across other admixed populations. Our findings reinforce the need for inclusion of more underrepresented populations in sequencing efforts to improve reference panels.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (13)

Daniel Mueller

Physician-in-Chief and Research Chair

University of Toronto

CANADA
View details

Maggie Waung

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Atsushi Takata

RIKEN

JAPAN
View details

Ana Paula Mendes-Silva

Assistant Professor

University of Saskatchewan

CANADA
View details

Caroline Nievergelt

Professor

University of California, San Diego

UNITED STATES
View details

Bradley J. MacIntosh

Senior Scientist

Sunnybrook Research Institute

CANADA
View details

Vanessa Gonçalves

Assistant Professor

University of Toronto

CANADA
View details

Ana Cristina Andreazza

Professor

University of Toronto

CANADA
View details

Elizabeth Atkinson

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Joyce So

University of California

UNITED STATES
View details

Shreejoy Tripathy

Associate Professor

University of Toronto

CANADA
View details

Paola Fadda

Full Professor

University of Cagliari

ITALY
View details

James Kennedy

University of Toronto

CANADA
View details